首页>投融资
Cellino
捐赠/众筹/授予
Cellino的使命是使患者能够获得个性化的自体细胞疗法。干细胞衍生的再生药物有望在这十年内治愈一些最棘手的疾病,包括帕金森氏症、糖尿病和心脏病。患者特异性细胞为这些适应症提供最安全、最有效的治疗方法。但是,由于大量手动处理、高可变性和昂贵的设施开销,当前的自体流程无法扩展。Cellino的愿景是首次使个性化再生药物大规模可行。
基本信息
-
公司全称Cellino Biotech Inc
-
类型细胞疗法开发商
-
产业领域药品研发/制造、生物药
-
公司人数15~50人
-
地址501 Massachusetts Ave.
-
联系电话
-
邮箱info@cellinobio.com
-
成立时间2017-01-01
投融资
-
2024-09-10捐赠/众筹/授予2500万美元ARPA-H
-
2022-01-25A轮8000万美元The EngineKhosla Ventures8VCFelicis VenturesHumboldt FundLeaps by Bayer
-
2021-02-01种子轮1600万美元The Engine8VCHumboldt FundKhosla Ventures
相关投融资企业
捐赠/众筹/授予
igaTx 是一家生物技术公司,开发工程化单体 IgA 中性粒细胞接合器,以释放中性粒细胞对癌症的肿瘤杀伤能力,以及针对传染病的工程化二聚体 IgA 杀伤能力。该公司在工程治疗性 IgA 方面的前沿方法基于 Jeanette Leusen 教授在乌得勒支医学中心(荷兰乌得勒支)进行的开创性工作,并广泛适用于许多不同疾病。
C轮
SiteOne Therapeutics, founded by Stanford University, is a biotechnology company focused on the development of long-acting analgesics, non-norcotic analgecis and diagnostic imaging agents for pain and cancer.In May 2023, SiteOne Therapeutics Inc received a grant for up to $15 million from the National Institute on Drug Abuse.In January 2017, the company raised $15 million in a series B round of financing
A轮
PsiOxus Therapeutics Ltd was formed from the merger of Myotec Therapeutics and Hybrid BioSystems in December 2010. The company is focused on the development of novel therapeutics that address cancer and other clinically unmet diseases.Myotec Therapeutics was a spin-out from Imperial Innovations and was set up to develop technology originated at Imperial College London. It focused on repurposing drugs for the treatment of cachexia, with the intention of out-licensing after completion of phase II studies.In June 2017, the company expanded its operations into a 21,000 sq ft state-of-the-art facility on the Abingdon Science Park in Oxfordshire, UK and a new US facility in Plymouth Meeting near Philadelphia, PA.In April 2012, PsiOxus announced that it would expand into new facilities at the Milton Park in Oxfordshire, UK. The expansion would include a bespoke laboratory for the research and development of novel viral therapeutics; later that month, the facility was opened.By Decem